ストックスクリーナーアプリを入手
204.03
0.47%
-0.96
アフターアワーズ：
204.03
Astrazeneca Plc (AZN) 最新ニュース
Parnassus Value Equity Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage - Yahoo Finance
Is AstraZeneca Still in Focus After Strong Market Momentum? - Kalkine Media
AstraZeneca Wins Strong Shareholder Backing at 2026 AGM - The Globe and Mail
AstraZeneca faces China headwinds and key drug launches as two banks back 20% upside - Yahoo! Finance Canada
AstraZeneca India Expands Cancer Drug Use, Stock Gains on Approval - Whalesbook
ASTRAZENECA : UBS gives a Buy rating - marketscreener.com
7MM Systemic Lupus Erythematosus and Lupus Nephritis Drug Market Analysis & Forecast 2024-2034: Future SLE and LN Players Competition, High Unmet Need for Steroid-sparing Treatments - GlobeNewswire Inc.
ASTRAZENECA : Jefferies reaffirms its Buy rating - marketscreener.com
PDL1 Antibody Reagent Market is Going to Boom: AstraZeneca • Pfizer • Novartis • Abcam - openPR.com
AstraZeneca shareholders approve all resolutions at annual general meeting - Investing.com
AstraZeneca shareholders approve all resolutions at annual general meeting By Investing.com - Investing.com UK
AstraZeneca (AZN) shareholders back all AGM resolutions and buyback - Stock Titan
AstraZeneca Triumphs at AGM: All Resolutions Passed - Devdiscourse
AstraZeneca announces all AGM resolutions including Special Resolutions 10-13 passed - marketscreener.com
AstraZeneca, Sun Dismiss Patent Suits Over Three Diabetes Drugs - Bloomberg Law News
Ideaya Biosciences announces clinical collaboration with AstraZeneca for lung cancer study - Investing.com India
$1.05 Bn Biopharmaceutical CXO MarketsGlobal Forecast Report 2026-2032: How Leading Pharmas Such as Pfizer, Roche, Novartis, Sanofi, and AstraZeneca Navigate the Evolving Dynamics - Yahoo Finance
IDEAYA Biosciences (NASDAQ: IDYA) teams with AstraZeneca on IDE849-Imfinzi SCLC trial - Stock Titan
Cowen Maintains Buy on AstraZeneca PLC (AZN) March 2026 - Meyka
AstraZeneca Wants 25 Opt-Ins Axed From Pay Bias Suit - Law360
AstraZeneca (NYSE: AZN) delists 0.700% Notes due 2026 from NYSE - Stock Titan
AstraZeneca Extends Fasenra’s Runway With New Long-Term Safety Study - TipRanks
AstraZeneca : Sustainability Data Reporting Criteria 2025 - marketscreener.com
AstraZeneca : Assurance Report for Sustainability Data Annex 2025 - marketscreener.com
AstraZeneca : Sustainability Data Annex 2025 - marketscreener.com
AstraZeneca Partners with Telangana Government to Introduce AI-Based Lung Cancer Screening - The Indian Practitioner
£20,000 invested in AstraZeneca shares 5 years ago is now worth… - Fool UK
Sit Dividend Growth Fund's AstraZeneca PLC(AZN) Holding History - GuruFocus
Top Research Reports for AstraZeneca, HSBC & Walt Disney - Yahoo Finance
Morgan Stanley raises AstraZeneca stock price target on pipeline progress By Investing.com - Investing.com UK
AstraZeneca, Telangana govt to roll out AI-powered lung cancer screening in public hospitals - The Times of India
What’s going on with the AstraZeneca share price now? - Fool UK
AstraZeneca's liver cancer breakthrough puts Imfinzi on course to become a super-blockbuster drug - Proactive Investors
AstraZeneca PLC (AZN) stock price, news, quote and history - Yahoo Finance Singapore
ASTRAZENECA : JP Morgan reiterates its Buy rating - marketscreener.com
AstraZeneca PLC (AZN) Stock Price, News, Quote & History - Yahoo! Finance Canada
AstraZeneca stock gains 1.77% as strong oncology-driven revenue and earnings growth boosts sentiment - Traders Union
Perpetual Ltd Has $515,000 Stock Holdings in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca Plc $AZN Stock Holdings Lowered by Cidel Asset Management Inc. - MarketBeat
AstraZeneca reports positive EMERALD-3 results for HCC - Clinical Trials Arena
AstraZeneca PLC (AZN.L) Stock Price, News, Quote & History - Yahoo! Finance Canada
AstraZeneca PLC (AZN.L) stock price, news, quote and history - Yahoo Finance UK
AstraZeneca: The Bigger Picture Remains Solid Growth Amidst Improving Margins And Returns - Seeking Alpha
Allspring Large Cap Growth Fund's AstraZeneca PLC(AZN) Holding History - GuruFocus
Aberdeen Group plc Grows Stake in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca (NYSE:AZN) Cut to Hold at Wall Street Zen - MarketBeat
FTSE AstraZeneca PLC Index (SSAZNS.FGI) Forum & Discussion - Yahoo! Finance Canada
SA T. Rowe Price VCP Balanced Portfolio's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca stock gains 1.77% as bullish technicals and positive trial results fuel buying - Traders Union
AstraZeneca PLC stock: Positive liver cancer trial results spark investor interest - AD HOC NEWS
AZN Stock Quote Price and Forecast - CNN
INTERNATIONAL CORE EQUITY 2 PORTFOLIO's AstraZeneca PLC(AZN) Holding History - GuruFocus
Astrazeneca (AZN) Rises Higher Than Market: Key Facts - Yahoo Finance
AstraZeneca (AZN) Faces New Tariff Challenges Amid U.S. Import D - GuruFocus
AstraZeneca’s New Cancer Combo Trial Signals Steady Progress in Antibody Drug Conjugates - TipRanks
AstraZeneca climbs Thursday, outperforms market - MarketWatch
Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,500 GBp From 16,000 GBp - Insider Monkey
AstraZeneca reports positive phase III results for Imfinzi and Imjudo in liver cancer - Investing.com
AstraZeneca (NYSE: AZN) liver cancer combo boosts PFS in Phase III - Stock Titan
AstraZeneca PLCImfinzi+Imjudo improves PFS in early liver cancer - Research Tree
AstraZeneca’s Liver Cancer Treatment Shows Promise in Phase III Trial - AskTraders
AstraZeneca's liver cancer therapy combo slows disease progression in late-stage trial - Reuters
AstraZeneca (AZN) Sees Success in EMERALD-3 Trial for Liver Canc - GuruFocus
1.03%
大文字化:
|
ボリューム (24 時間):